ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Viral therapy"

  • 2017 American Transplant Congress

    Influenza Viral Dynamics in a Large Cohort of Transplant Patients with Natural Influenza Infection.

    V. Ferreira,1 A. Humar,1 E. Cordero,2 E. Blumberg,3 A. Limaye,8 F. Silveira,5 L. Danziger-Isakov,6 M. Levi,7 J. Kalpoe,4 J. Englund,9 M. Multicenter Influenza Group, D. Kumar.1

    1UHN, Toronto, Canada; 2REIPI, Seville, Spain; 3UPenn, Philadelphia; 4LUMC, Leiden, Netherlands; 5UPMC, Pittsburgh; 6CCHMC, Cincinnati; 7UCD, Denver; 8UW, Seattle; 9SCH, Seattle

    Background:Influenza infection significantly impacts transplant patients. Despite this, there are limited data on how virological characteristics, including influenza viral load (VL), impact the outcome of…
  • 2017 American Transplant Congress

    A Single Center's Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving an HCV Positive Kidney.

    N. Kapila,1 B. Zervos,2 B. Ismail,1 G. Schnickel,2 J. Rivas,2 D. Reino,2 N. Agrawal,2 A. Tzakis.2

    1Gastroenterology/Hepatology, Cleveland Clinic, Weston, FL; 2Transplant, Cleveland Clinic, Weston, FL

    Background: Nearly 8% of patients in the U.S. undergoing hemodialysis are Hepatitis C (HCV) positive. There is a survival benefit in HCV positive patients who…
  • 2017 American Transplant Congress

    Mutations in Influenza A Virus and Clinical Implications in Transplant Recipients.

    V. Ferreira,1 A. Humar,1 E. Cordero,2 E. Blumberg,3 S. Husain,1 J. Kalpoe,4 M. Multicenter Influenza Group, D. Kumar.1

    1UHN, Toronto, Canada; 2REIPI, Seville, Spain; 3UPenn, Philadelphia; 4LUMC, Leiden, Netherlands

    Background: Organ and hematopoietic stem cell transplant (HSCT) recipients are predisposed to complications of influenza infection and as such may constitute an important source of…
  • 2017 American Transplant Congress

    Hepatitis E Virus-Associated Cryoglobulinemia in Solid-Organ-Transplant Recipients: A Prospective Study.

    O. Marion,1 F. Abravanel,2 L. Esposito,1 S. Lhomme,2 A. Del Bello,1 J. Izopet,2 N. Kamar.1

    1Nephrology and Organ Transplant Unit, CHU Rangueil, Toulouse, France; 2Laboratory of Virology, CHU Purpan, Toulouse, France

    Hepatitis E virus (HEV) is responsible for acute and chronic autochthonous hepatitis in developed countries, particularly in Western Europe. Conversely to hepatitis B or C,…
  • 2017 American Transplant Congress

    Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Solid Organ Transplant Recipients: A Phase 2 Study.

    M. Pereira,1 F. Silveira,2 G. Papanicolaou,3 A. Langston,4 R. Avery,5 A. Wijatyk,6 J. Wu,6 M. Boeckh,7 F. Marty,8 S. Villano.9

    1Columbia University Medical Center, New York, NY; 2University of Pittsburgh Medical Center, Pittsburgh, PA; 3Memorial Sloan Kettering Cancer Center, New York, NY; 4Winship Cancer Institute, Atlanta, GA; 5Johns Hopkins University, Baltimore, MD; 6Shire, Lexington, MA; 7Fred Hutchinson Cancer Research Center, Seattle, WA; 8Brigham and Women's Hospital, Boston, MA; 9Shire (At Time of Study), Wayne, PA

    Study NCT01611974 assessed safety, tolerability, and antiviral activity of maribavir (MBV) for treatment of resistant or refractory (R/R) CMV infections among transplant recipients. Those aged…
  • 2017 American Transplant Congress

    Low Dose Valganciclovir for CMV Prophylaxis in the First Year of Kidney Transplantation.

    P. Klem,1 L. Al-Omar,2 J. Cooper,2 S. Davis,2 J. Gralla,2 D. Choe,1 A. Wiseman.2

    1Pharmacy, University of Colorado, Aurora, CO; 2Nephrology, University of Colorado, Aurora

    Valganciclovir (VGC) is the standard antiviral agent used for the prevention of CMV diseases in moderate and high risk renal transplant recipients, yet the optimal…
  • 2017 American Transplant Congress

    Subclinical Rejections in Kidney Transplant Recipients Treated with Direct Acting Antiviral Agents for Hepatitis C Treatment within 1 Year of Transplant.

    T. Rege,1 K. Hatahet,1 A. Gillespie,1 M. Ghanta,1 I. Lee,1 K. Qureshi,1 K. Lau,2 S. Karhadkar,2 A. DiCarlo,2 S. Constantinescu,1 S. Rao.1

    1Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA; 2Surgery, Temple University, Philadelphia, PA

    Direct acting antiviral agents (DAA) have revolutionized the management of Hepatitis C virus (HCV) positive kidney transplant recipients (KTR). The optimal timing of DAA therapy…
  • 2016 American Transplant Congress

    Prophylactic Anti-Virus Therapy, Is It Necessary to Occult Hepatitis B Virus Carriers with HBsAg(-) and HBcAb(+) After Kidney Transplantation?

    G. Chen, C. Wang, L. Chen, J. Qiu, C. Wang.

    Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.

    Background Hepatitis B virus(HBV) infection is common among uremia patients in China. Many patients received kidney transplantation are occult HBV carriers with HBsAg(-) and HBcAb(+)…
  • 2016 American Transplant Congress

    Descriptive Epidemiology and Trends of Community Parenteral Antimicrobial Therapy Utilization Among Solid Organ Transplant Recipients at a High Volume Transplant Center 2008 to 2014.

    S. Mawhorter, N. Shrestha.

    Infectious Diseases, Cleveland Clinic, Cleveland, OH.

    INTRODUCTION: Solid organ transplant (SOT) recipients may benefit from community-based parenteral anti-infective therapy (CoPAT). Limited data are available. CoPAT may help reduce LOS. As a…
  • 2016 American Transplant Congress

    Is SVR Associated with Improved Hepatic Function in Hepatitis C Gen 1 Pts with Cirrhosis 1 Year After Completing Treatment with Sofosbuvir + Simeprevir +/- Ribavirin?

    A. Modi,1 J. Hermann,1 H. Nazario,2 S. Gonzalez,1 J. Gripshover,3 M. Gautam,1 J. Weinstein,2 D. Potosky,3 M. Barnes,2 A. Habib,2 P. Mantry,2 J. Trotter.1

    1Liver Consultants of Texas, Dallas-Fort Worth, TX; 2Liver Institute Methodist, Dallas, TX; 3University of Maryland, Baltimore, MD.

    Background: Combination antiviral therapy involving Sofosbuvir (SOF) & Simeprevir (SIM) +/- Ribavirin (RBV) is a relatively safe & effective Tx option in pts with gen…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences